The North American biopharmaceuticals market, valued at US$ 151.22 billion in 2022, is projected to reach US$ 315.74 billion by 2028, exhibiting a Compound Annual Growth Rate (CAGR) of 13.1% from 2022 to 2028. This growth is significantly fueled by the increasing potential to treat rare diseases.
📚Download Full PDF Sample Copy of Market Report @https://www.businessmarketinsights.com/sample/BMIRE00028630
According to the National Institute of Health (NIH), approximately 10% of the US population (30 million Americans) is affected by one of the 7,000 known rare diseases. While developing treatments for these conditions presents scientific and operational complexities due to their intricate biology, biopharmaceutical researchers in North America have made significant strides, leveraging new technologies to develop groundbreaking therapies. Over the past decade, the US FDA has approved 350 orphan drugs, particularly for conditions with limited or no existing treatments. For instance, Transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and progressive cardiovascular disease with a median life expectancy of only 2.5-3.5 years if untreated, is a prime target for these advancements. Furthermore, Ultragenyx Pharmaceutical Inc. is actively involved in clinical studies (initiated December 2021) for UX053, an mRNA-based therapy for Glycogen Storage Disease (GSD) type 3, a severe rare genetic disorder. UX053 aims to be the first potential medicine for GSD3, capable of delivering large genes to targeted cells for high protein expression uniformity, with plans for individualized mRNA therapies. Such clinical developments, product launches, and approvals are significantly propelling the North America biopharmaceuticals market.
Geographically, the North America biopharmaceuticals market encompasses the US, Canada, and Mexico. The region’s market expansion is primarily driven by the rising incidence of cancer, the continuous introduction of new products, and technological advancements within the biopharmaceutical sector. The biopharmaceuticals industry is at a critical juncture, holding immense promise for revolutionizing the treatment of costly and debilitating diseases such as Alzheimer’s, cancer, heart disease, and hepatitis C.
The US plays a pivotal role in this growth, driven by a growing burden of chronic diseases and substantial investments in research and development. The US leads globally in R&D investment and innovation, with over 3,400 drugs in clinical development as of 2020, representing nearly half of the estimated 8,000 drugs worldwide (including 1,100 for various cancers). The biopharmaceuticals industry contributes significantly to the US economy, both directly and indirectly. In 2018, pharmaceutical and medical manufacturing accounted for 0.95% of private sector value added, with biotech R&D facilities contributing an additional 0.23%. The high prevalence of chronic conditions further underscores the market’s potential; for example, data from the Centers for Disease Control and Prevention (CDC) in July 2022 indicated that approximately 20.1 million adults aged 20 and older in the US suffer from coronary artery disease, with nearly 805,000 Americans experiencing a heart attack annually. These factors are expected to substantially boost the North America biopharmaceuticals market throughout the forecast period.
North America Biopharmaceuticals Strategic Insights
Strategic insights for the North America Biopharmaceuticals provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
Market leaders and key company profiles
ï‚· AbbVie Inc
ï‚· AGC Biologics AS
ï‚· Amgen Inc
ï‚· Boehringer Ingelheim International GmbH
ï‚· Bristol-Myers Squibb Co
ï‚· Eli Lilly and Co
ï‚· Johnson & Johnson
ï‚· Lonza Group AG
ï‚· Thermo Fisher Scientific Inc
ï‚· WuXi Biologics Inc
North America Biopharmaceuticals: Tailoring Strategies for Regional Success
Understanding the distinct geographic landscapes within North America is paramount for biopharmaceutical companies. Local variations in consumer preferences (e.g., demand for specific treatments or healthcare services), economic conditions, and regulatory environments necessitate a tailored approach. By recognizing these regional differences, businesses can identify underserved markets, adapt their offerings to meet specific local demands, and optimize resource allocation. A clear market focus enables more effective targeted marketing and stronger competitive positioning, ultimately driving growth across North American biopharmaceutical markets.
The North America biopharmaceuticals market is categorized by product type, application, and country.
Product Type Segmentation:
- Monoclonal Antibodies: Held the largest market share in 2022.
- Recombinant Vaccines:
- Cancer vaccine
- Malaria vaccine
- Ebola vaccine
- Hepatitis-B vaccine
- Tetanus vaccine
- Diphtheria vaccine
- Cholera vaccine
- Others
- Conventional Vaccines:
- Polio vaccine
- Pox vaccine
- Others
- Recombinant Growth Factors:
- Erythropoietin
- Granulocyte colony stimulating factor
- Purified Proteins:
- Leukemia inhibitory factor (LIF)
- P53 protein
- P38 protein
- Others
- Recombinant Proteins:
- Serum albumin
- Amyloid protein
- Defensin
- Transferrin
- Recombinant Hormones:
- Recombinant human growth hormones
- Recombinant insulin
- Other recombinant hormones
- Recombinant Enzymes:
- Enterokinase
- Cyclase
- Caspase
- Cathepsin
- Cell & Gene Therapies:
- Allogenic products
- Autologous products
- Acellular products
- Cytokines/Interferon/Interleukins
- Others
Application Segmentation:
- Oncology: Held the largest market share in 2022.
- Inflammatory & Infectious Disease
- Autoimmune Disorders
- Metabolic Disorders
- Hormonal Disorders & Growth Failure
- Cardiovascular Diseases
- Neurological Diseases
- Others
Country Segmentation:
- US: Accounted for the largest market share in 2022.
- Canada
- Mexico
Key Players in the North America Biopharmaceuticals Market:
- AbbVie Inc
- AGC Biologics AS
- Amgen Inc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Eli Lilly and Co
- Johnson & Johnson
- Lonza Group AG
- Thermo Fisher Scientific Inc
- WuXi Biologics Inc
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Défense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
Author’s Bio
Akshay
Senior Market Research Expert at Business Market Insights
